News | Stents Drug Eluting | September 30, 2019

Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

Results from the IDEAL-LM Study reported at TCT 2019

Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT.

Findings were reported at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Sept. 25-29 in San Francisco, sponsored by the Cardiovascular Research Foundation (CRF).

Continuous improvements in stent technology make PCI a potential alternative to surgery in selected patients with uLMCA disease. The optimal duration of DAPT in these patients after PCI remains undetermined and new stent designs using a bioabsorbable polymer may allow a shorter duration of DAPT.

IDEAL-LM is a prospective, randomized, multicenter study conducted at 29 sites in five countries. Between December 2014 and September 2016, a total of 818 patients were randomized 1:1 to BP-EES or to DP-EES. Procedural success was 99.9 percent, predominantly using single-stent techniques (79.6 percent). DAPT was stopped at four months in the BP-EES arm but continued for 12 months after PCI in the DP-EES arm. The primary endpoint assessment was a non-inferiority comparison of major adverse cardiovascular events (MACE) rate, including death from any cause, myocardial infarction or ischemia-driven target vessel revascularization (TVR) at two years after the procedure. Key secondary endpoints included ischemic and bleeding events.

The primary endpoint of non-inferiority for MACE at 24 months was met with 14.6 percent in the BP-EES group (n=403) compared to 11.4 percent in the DP-EES (n=396) group (p= 0.17). There were no differences in ischemic events, including no difference in stent thrombosis, between four and 12 months when the antiplatelet therapy was reduced in the BP-EES arm. However, this strategy did not result in a reduction of BARC 3 or 5 bleeding in the short DAPT group, with low-bleeding occurring in both study arms (2.7 percent for BP-EES versus 0.5 percent for DP-EES, p=0.02).

“IDEAL-LM confirms the excellent outcomes of current angioplasty techniques in patients with left main coronary artery disease,” said Prof. Robert-Jan Van Geuns, M.D., Ph.D., an interventional cardiologist at RadboudUMC, Nijmegen, The Netherlands and co-principal investigator of the study. “In addition, short DAPT is an option after angioplasty for left main disease with the latest DES design.” 

Prof. Keith G. Oldroyd of the Golden Jubilee National Hospital, the other co-principal investigator, commented that the somewhat surprising data on bleeding was likely due to the use of oral anticoagulation in some of the patients who bled and pointed out that the trial was not powered for bleeding events.

The IDEAL LM study was funded by Boston Scientific. The Golden Jubilee National Hospital, Glasgow, United Kingdom, served as sponsor. Van Geuns reports receiving speaker fees from Boston Scientific, Abbott Vascular and AstraZeneca. Oldroyd reports receiving speaker fees from Abbott Vascular and Biosensors and institutional research support from Boston Scientific.

More late-breaking coverage from TCT 2019

For more information: www.crt.org/tct


Related Content

News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Subscribe Now